Categories: All postsAnalysts

ProntoForms is still a buy, PI Financial says

Ahead of the company’s fourth quarter results, PI Financial analyst David Kwan has maintained his “Buy” rating on ProntoForms (ProntoForms Stock Quote, Chart, News TSXV:PFM).

On on Thursday, March 12th, before the market open, ProntoForms will report its Q4 and fiscal 2019 results. Kwan said he is expecting fourth quarter EBITDA of negative $300,000 on revenue of $4.1-million.

Kwan said he is anticipating an acceleration in recurring revenue growth from PFM.

“We are forecasting Q4 recurring revenue of $3.8M (up 28% YoY and 8% QoQ; all organic), an acceleration from recent quarters where YoY growth was 26% and QoQ growth has been in the ~4.5%-6.0% range, the analyst said. “We expect this stronger recurring revenue growth to continue into FY20, as PFM benefits from the ramp in productivity from the many additions to its sales team over the last year, with PFM still actively looking to add to its growing sales team given the large greenfield opportunity ahead, including significantly increasing the penetration within its many large enterprise customers.


This article brought to you by
WELL HEALTH TECHNOLOGIES (TSX:WELL)

WELL Health Technologies has launched VirtualClinic+, a comprehensive Telehealth program across Canada. Due to the COVID-19 epidemic, WELL plans to rapidly ramp up the program. Click here for more info.


Kwan adds that recent weakness in the Canadian dollar could be a tailwind for the company.

“The recent decline in the Canadian dollar could provide a modest tailwind for PFM. With the Company reporting in US$, it could see a slight headwind from a revenue perspective from the weaker C$ (~10-15% of revenue is generated in Canada) but it should see a positive impact to its bottom line, given the majority of its costs are in C$.

In a research update to client today, Kwan maintained his “Buy” rating and one-year price target of $1.10 on ProntoForms, a figure that implied a return of 48.6 per cent at the time of publication.

Kwan thinks PFM will post Adjusted EBITDA of negative $1.2-million on revenue of $15.2-million in fiscal 2019. He expects those numbers will improve to EBITDA of negative $800,000 on a topline of $20.3-million the following year.

The analyst added that the company has limited COVID-19 exposure.

“As a SaaS company, PFM has no exposure to COVID-19 as it relates to manufacturing or its supply chain,” he said. “However, there could be some demand headwinds, as it relates to delayed decision making by (potential) customers as well as possible reduced customer spending due to concerns over a related slowing (global) economy, although these risks are also faced by companies elsewhere.”

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: pfm
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

JUSH stock is a buy, Beacon says

With its first quarter results on deck, Beacon Securities analyst Russell Stanley thinks Jushi Holdings (Jushi Holdings Stock Quote, Chart,… [Read More]

8 mins ago

Is Curaleaf stock still a buy?

The stock has been a steady climber since last October, but ahead of earnings is Curaleaf (Curaleaf Stock Quote, Chart,… [Read More]

2 hours ago

OpenText price target cut at National Bank

Following third quarter results he describes as "in-line", National Bank Financial analyst Richard Tse has cut his price target on… [Read More]

3 hours ago

Silicon Motion stock still a buy, Roth says

Following the company's first quarter results, Roth MKM analyst Suji Desilava remains bullish on Silicon Motion Technology (Silicon Motion Technology… [Read More]

4 hours ago

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

3 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

3 days ago